Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jeffrey_Goldberg
|
| gptkbp:clinicalTrialPhase |
Phase 1 (IMT-009)
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
immuno-oncology
|
| gptkbp:foundedYear |
2019
|
| gptkbp:founder |
gptkb:Longwood_Fund
|
| gptkbp:fundedBy |
gptkb:Leaps_by_Bayer
gptkb:M_Ventures gptkb:Evotec gptkb:Novartis_Venture_Fund Agent Capital Genoa Ventures NSV Partners |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunitas Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:products |
IMT-009
IMT-1C |
| gptkbp:specializesIn |
cancer therapeutics
single cell genomics |
| gptkbp:therapeuticArea |
solid tumors
hematologic malignancies |
| gptkbp:website |
https://immunitastx.com/
|
| gptkbp:bfsParent |
gptkb:Vida_Ventures
|
| gptkbp:bfsLayer |
8
|